+What's unique about Amazon for supplement brands?
Three things: FDA structure-function claim rules limit what your listing copy can say, Amazon's restricted-product policies require additional compliance documentation for many supplement categories, and counterfeit and grey-market sellers attack supplement listings more aggressively than almost any other category. An agency without supplement fluency will get your listings suppressed, your ASINs flagged, and your Buy Box stolen.
+Should I run subscribe-and-save aggressively as a supplement brand?
Yes if your repeat-purchase economics support it. Subscribe-and-save attach above 25% changes the LTV math meaningfully, which means you can profitably acquire customers at higher CPC than a single-purchase category would tolerate. The right agency builds the ad bidding strategy around 90 to 120 day LTV, not first-purchase profit.
+How does Eleviam handle Amazon claim suppressions for supplements?
We pre-audit every listing change against Amazon's restricted-product policy and FDA structure-function rules before publishing. When suppressions happen anyway (Amazon's automated systems flag false positives constantly), we run the appeal process with documentation kits we keep current. Most appeals resolve in 24 to 72 hours.
+What's the typical TACoS benchmark for supplement brands?
Healthy supplement TACoS lands at 15 to 22%, slightly higher than the broader CPG benchmark, because subscribe-and-save attach lets you absorb higher acquisition cost and because branded defense (protecting against grey-market sellers bidding on your name) is a structural cost. Brands above 30% TACoS without an aggressive scale-mode rationale almost always have fixable structural problems.
+Should I consider 3P distribution as a supplement brand?
Yes if capital is the actual bottleneck. Supplement gross margins are usually high enough (35 to 60%) to support both the brand wholesale margin and the 3P partner's resale margin. The 3P Exclusive partnership transfers inventory and ad-spend risk to Eleviam, which often unlocks the aggressive scaling that supplement repeat-purchase economics already justify but the brand can't fund.
